33results about How to "Improved tissue penetration" patented technology

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also provided.

The invention provides a targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof. The targeting nano carrier comprises DNA tetrahedron, Affibody molecule and nucleoside anti-tumor drugs. The preparation method comprises the following steps: a, the nucleoside anti-tumor drugs are modified with phosphoramidite; B, synthesizing four DNA single strandsby DNA solid phase synthesis technology, integrating the nucleoside anti-tumor drugs into the 5 'ends of the four DNA single strands, and modifying NH2 at the 3' ends of one of the DNA single strands; C, linking the affibody molecule to the 3 'end of the NH2-modified DNA single strand through a linker; (d) mix and assembling that four DNA single strand in a molar ratio of 1: 1: 1: 1 to obtain DNAtetrahedron; and (d) assembling the four DNA single strands in a molar ratio of 1: 1: 1 to obtain DNA tetrahedron; Affibody targeting nanoparticles. The targeting nano carrier of the invention can precisely control the combined quantity of drugs, has faster tumor targeting ability and higher cell, tissue penetration ability, good pharmaceutical effect, and is suitable for popularization and application.

The invention discloses a virus-like hollow oxide loaded near-infrared two-b region excited rare earth nanocrystal and a preparation method and application thereof. According to the nanocrystal and the preparation method, an Er and Ho doped NaErF4:2%Ho@NaYF4 rare earth nanomaterial is synthesized through a hydrothermal method, then the nanomaterial is modified on a surface of a virus-like hollow manganese oxide poured into IR1064 through an amidation reaction, and a fluorescent composite probe which is good in biocompatibility and responds to a tumor microenvironment is obtained. According to the fluorescent composite probe, after the manganese oxide is degraded at a tumor, manganese ions are used for chemodynamic therapy and nuclear magnetic resonance imaging contrast agents of metastasis, released rare earth nanocrystals have excitation of 1530 nm and emitted lights of 650 nm and 1180 nm, the light of 1180 nm can be used for tumor imaging navigation surgical resection with no background interference and high resolution and tissue penetrating power in a near-infrared second region, and the light of 650 nm can used for near-infrared first region fluorescence imaging.

The invention discloses a magnetic composite nano material and a preparation method and application thereof. The magnetic composite nano material comprises modified magnetic nano particles and a modified macromolecular layer located on the outer surfaces of the modified magnetic nano particles, wherein the modified macromolecular layer comprises macromolecules and polymers connected with the macromolecules through pH response groups, and the response pH value of the pH response groups is smaller than 6.8. The magnetic composite nano material exists in a cluster form before reaching a tumor part, and due to the large particle size, the magnetic composite nano material is not likely to be rapidly removed by kidney metabolism; after the magnetic composite nano material reaches the tumor part,an assembly (the magnetic composite nano material) is gradually dispersed under the tumor subacid condition, the magnetic composite nano material exists in the tumor part in a small-particle-size magnetic nano particle form, and therefore the penetration depth of tumor tissue is increased; and due to falling of the surface modification polymers, surface positive charges are increased, and the nano particles are more easily taken by cells. Therefore, the pH response type magnetic composite nano material cluster enhances the MRI imaging contrast effect and improves the tissue penetration.

The invention discloses a medicine delivery system for realizing specificity nanometer antibody medicine delivery through the vagina for the first time, and a preparation method and application thereof. The vector recipe is optimized, so that the nanometer antibody stability and the tissue penetration are maintained and enhanced; the application of the nanometer antibody vagina medicine delivery system to disease treatment and woman sanitation care is realized. Through the nanometer antibody vagina medicine delivery, the specificity nanometer antibody can realize the medicine effect in the vagina internal environment and positions near the organ local part; in addition, the nanometer antibody can penetrate through vagina tissues to enter human body blood for circulation; the goal of achieving the medicine effect in the preset focus position is realized. The nanometer antibody vagina medicine delivery system has the advantages that medicine is slowly released in the woman vagina and through vagina cortical tissues; no basic irritation and allergic reaction exists; the safe and efficient medicine delivery mode and the new dosage form of nanometer antibody biological medicine are opened up; the application prospects are very wide.

The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused; a method for prepraring an anti-VEGF preparation, which overcomes resistance and has an improved efficacy, the method comprising the steps of transforming a host cell with a recombinant vector comprising a nucleic acid sequence encoding a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, culturing the cell, and recovering a fusion protein from the cell; a method for treating eye diseases, comprising administering an effective dose of the fusion protein according to the present invention to a subject in need thereof; and use of the fusion protein according to the present invention for preparing an agent for treating eye diseases. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have an improved efficacy and be able to be used for treating patients having drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing pericyte coverage. In addition, since drug delivery ability into the choroid tissue is improved when performing an intraocular injection, the composition can be developed as eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability.

The invention discloses a NIR-II imaging probe and a preparation method and application thereof, and belongs to the technical field of in vivo bioluminescence imaging of cells. The invention comprisesthe following steps: S1, incubating bone marrow mesenchymal stem cells (BMSCs) of fluorescent probe CP@mSiO2(subscript)-PEG nanoparticles; S2, injecting fluorescent material-labeled BMSCs into HepG2tumor-bearing nude mice through tail vein injection and local subcutaneous injection; and S3, carrying out near-infrared-II (NIR-II) window imaging on the tumor, and then performing imaging-guided tumor resection. In the study, NIR-II is a new strategy for tumor imaging in vivo and image-guided tumor resection surgery, the NIR-II in vivo bioluminescence imaging technology is used to induce the fluorescent material-labeled BMSCs to enrich in the tumor site, so that the outline of the tumor can be seen clearly, thus improving the accuracy of surgical resection and reducing the tumor recurrence rate and the mortality rate.

There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.

The invention relates to application of micelles formed by polyethylene glycol derivatives in paclitaxel or derivatives thereof, and belongs to the technical field of lipoid molecules. The polyethylene glycol derivative can be dispersed in a solvent to form micelles, and the micelles can be used for efficiently wrapping, delivering and releasing paclitaxel or paclitaxel derivatives. Micelles formed by the polyethylene glycol derivative have high tissue penetrability, long-acting stability and controllable release performance. Particularly, the polyethylene glycol derivative contains a phospholipid structure, so that the polyethylene glycol derivative has outstanding biocompatibility.

A method for HIFU treatment of localized prostate cancer in a patient includes identifying the cancer locations in a patient's prostate; visually segmenting the patient's prostate into areas for analysis and treatment, where the section including the area of most aggressive cancer is determined to be the primary area. The primary area is subjected to a first full HIFU treatment for a period intended to ablate the cancerous tumor. HIFU treatment is then stopped on the primary area and the primary area is allowed to rest while simultaneously subjecting the next contiguous area of the patient's prostate to a first HIFU treatment to ablate any additional areas of suspected cancer in the next contiguous area. HIFU treatment is then stopped in the contiguous area. The primary area is then subjected to a second full HIFU treatment for a period sufficient to ensure the complete ablation of the cancerous tumor. The method further includes repeating alternating full HIFU treatment processes on subsequent contiguous areas of the patient's prostate to ensure the complete ablation of any cancerous tumors in the patient's prostate. The entire process is completed under one treatment of anesthesia.

The invention provides a novel acid response ionic liquid microcapsule as well as a preparation method and application thereof. The ionic liquid microcapsule comprises an inner core and a shell layer, wherein the inner core is ionic liquid, and the shell layer is a metal-polyphenol network coating. The preparation method of the microcapsule comprises the following steps: adding polyphenol into the ionic liquid, and performing stirring to dissolve the polyphenol to obtain polyphenol-ionic liquid; adding the polyphenol-ionic liquid into water, and performing ultrasonic and uniform dispersing; and then adding a metal ion solution, performing whirling to uniformly mix the system, then adjusting the pH value of the system, and performing centrifuging to obtain the microcapsule. According to the ionic liquid microcapsule prepared by the method, the stability of ionic liquid droplets can be remarkably improved, and various drug molecules, especially indissolvable drugs, can be effectively loaded; and MPN of the prepared microcapsule is dissociated in an acidic microenvironment, so that the ionic liquid carries the medicines to permeate into a target tissue, and the utilization rate of the medicines is greatly improved and the efficacy of the medicines is enhanced due to the relatively strong medicine permeation effect of the ionic liquid.

The invention provides photodynamic therapeutic compounds and photodynamic methods of treatment. The photodynamic therapeutic compounds may be activated by long wavelength light. The photo-activation by long wavelength light may allow improved tissue penetration. The compounds are selected from the group consisting of compounds of formula (i), or a pharmaceutically acceptable salt thereof: formula (i) wherein PDC is a photodynamic core and wherein R1; R2; R3; and R4 are H, phenyl, pyridine-4-yl, methylpyridinium, N-methylpyridinium-3-yl; 2-phenyl-N-methylpyridinium-4-yl, 3-phenyl-N-methylpyridinium-4-yl, 4-phenyl-N-methylpyridinium-4-yl, 2-phenyl-N-methylpyridinium-3-yl, 3-phenyl-N-methylpyridinium-3-yl or 4-phenyl-N-methylpyridinium-3-yl; and wherein any one or more of R1, R2, R3 and R4 may be optionally substituted.